The massive EPS beat is entirely from volatile investment portfolio gains (Armata), which are not recurring. Revenue miss and operating income decline signal underlying softness in the core royalty business. Watch for NUZOLVENCE launch in H2 2026 as a potential catalyst, but the stock's reaction may be muted by the non-operational nature of the earnings beat.
Price Chart
Executive Summary
Innoviva reported Q1 2026 total revenue of $98.0M (+11% YoY, slightly below $101.6M consensus) and diluted EPS of $2.22, dramatically above the $0.43 consensus, driven by $191.2M in non-operating investment gains (primarily Armata Pharmaceuticals). Operating income declined to $38.2M from $41.4M a year ago, reflecting higher SG&A and R&D spend. The core royalty portfolio continued to slide (gross royalties -4% YoY), while IST product sales grew 37%.
Key Financial Metrics
Key Facts
- Total revenue $98.0M vs consensus $101.6M (miss of ~3.5%)
- Diluted EPS $2.22 vs consensus $0.43 (beat of ~416%)
- Operating income $38.2M vs $41.4M in Q1 2025 (-7.7%)
- Net income $186.6M included $191.2M net favorable change in fair value of equity investments
- IST U.S. net product sales grew 29% YoY to $34.2M
- Gross royalty from GSK declined to $58.6M from $61.3M (-4.4%)
- Repurchased 971,066 shares for $20.4M during Q1
- Cash and equivalents $603.1M as of March 31, 2026
Financial Impact
EPS over 5x consensus due to non-cash investment gains; revenue slightly below expectations
Risk Factors
- Royalty revenue from GSK continues to decline, pressuring top line
- Operating income contraction due to rising SG&A and R&D costs
- Investment gains are non-cash and subject to market volatility
- NUZOLVENCE commercialization may underperform expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-209044 |
| Document: d54063d8k.htm | 0001193125-26-209044 |
| Document: 0001193125-26-209044-index-headers.html | 0001193125-26-209044 |
| Document: 0001193125-26-209044-index.html | 0001193125-26-209044 |
| Document: 0001193125-26-209044.txt | 0001193125-26-209044 |
| 8-K Data (Synthetic) | 0001193125-26-209044 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 18, 2026 19w ago | 8-K | $21.73 $20.75 | ▼ −4.51% | ▼ −10.80% | $20.50 (−5.66%) |
May 6, 2026 21w ago | 8-K | $22.80 $20.77 | ▼ −8.90% | ▼ −12.74% | $20.50 (−10.09%) |
Mar 27, 2026 27w ago | 10-K/A | $22.91 $23.35 | ▲ +1.92% | ▼ −14.57% | $20.50 (−10.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access